Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: Long-term effects of perinatal phencyclidine administration

Radonjić, Nevena V.; Knežević, Iva D.; Vilimanovich, Urosh; Kravić-Stevović, Tamara; Marina, Ljiljana; Nikolić, Tatjana; Todorović, Vladimir S.; Bumbaširević, Vladimir; Petronijević, Nataša

doi:10.1016/j.neuropharm.2009.12.009

Cited by 71 publications

(41 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies have shown a decrease in the GSH level in CSF in drug-naive patients and in animal models of schizophrenia, supporting the hypothesis of an impaired antioxidant defence system in the pathophysiology of the disorder (Do et al, 2000;Radonjić et al, 2010). In contrast to those studies, we did not find any differences in GSH levels in plasma or CSF between patients and controls.…”

Section: Discussionsupporting

confidence: 62%

Taurine and glutathione in plasma and cerebrospinal fluid in olanzapine treated patients with schizophrenia

Samuelsson

Skogh

Lundberg

et al. 2013

Psychiatry Research

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 62%

Taurine and glutathione in plasma and cerebrospinal fluid in olanzapine treated patients with schizophrenia

Samuelsson

Skogh

Lundberg

et al. 2013

Psychiatry Research

View full text Add to dashboard Cite

“…This indicates different degrees of oxidative stress in different brain areas in schizophrenics. Radonjic, et al [8] confirmed this finding in animal studies in which phencyclidine-fed perinatal Wister rats were used to produce schizophrenic animal models. It was found that lipid peroxidation levels in the hippocampus and thalamus areas were significantly increased.…”

Section: Elevated Indicator Level Of Oxidative Stress In Schizophreniamentioning

confidence: 78%

Oxidative Stress and Schizophrenia

2017

J Psychiatry Brain Sci.

View full text Add to dashboard Cite

Many studies show that oxidative stress is a pathophysiological mechanism of schizophrenia. Elevated oxidative stress levels and the damage to the antioxidant defense system can observed in early schizophrenia. High oxidation levels damage lipids, proteins, nucleic acids and other tissues. Antioxidant defense system imbalance has been observed in both neuroleptic-naïve first-episode schizophrenics and chronic schizophrenics being treated with medication and indicates the presence of oxidative stress in schizophrenia.Antipsychotic drugs also exert certain impacts on oxidative stress while improving the schizophrenia clinical symptoms. Antioxidants synergistically improve schizophrenia clinical symptoms. A combination regime of antipsychotic drugs and antioxidants is a potentially effective treatment strategy for schizophrenia.Keywords: Schizophrenia; Oxidative stress; Antioxidant defense system; Antioxidants.Schizophrenia is a common, serious mental illness, usually associated with, among other things, disordered perceptions, thoughts, emotions, volition and behavior. Major symptoms include positive symptoms (e.g. delusions or hallucinations), negative symptoms (i.e. affective flattening, alogia, or avolition) and cognitive dysfunction. The precise etiology of the disease remain unclear and both genetic and environmental factors appear to be involved. Recently scholars and researchers have begun to study the effect of oxidative stress on schizophrenia pathophysiology and it is thought to be involved in schizophrenia generation and development. This study reviews, and summarizes, schizophrenia pathogenesis, and oxidative stress medication therapy. Oxidative stress explained first, followed by a discussion of its relationship to schizophrenia. It then discusses http://jpbs.qingres.com

show abstract

“…In animal models of schizophrenia, perinatal phencyclidine (an NMDA receptor antagonist) administration increased the level of lipid peroxides in rats [124], while ketamine (an NMDA antagonist) injections to mice increased lipid [125,126] and protein [126] peroxidation and raised superoxide levels [127]. In genetic models, there were either increased levels of oxidized lipids in G72/G30 transgenic schizophrenic mice [128] or elevated cortical ROS production in g-aminobutyric acid-ergic interneuron-specific NMDAR hypofunction mice (Ppp1r2-Cre/ fGluN1 knockout [KO] mice) [129] (Table 1).…”

Section: Animal Studiesmentioning

confidence: 99%

“…Perinatal phencyclidine or ketamine administration to rodents evoked depletion of the reduced GSH and several changes in enzymes activities [124,126] (see Table 1). In genetic models, there are several lines of evidence that oxidative stress plays a role in the pathogenesis of schizophrenia.…”

Section: Animal Studiesmentioning

confidence: 99%

Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism

Smaga

Niedzielska

Gawlik

et al. 2015

Pharmacological Reports

224

123

View full text Add to dashboard Cite

The pathophysiology of psychiatric diseases, including depression, anxiety, schizophrenia and autism, is far from being fully elucidated. In recent years, a potential role of the oxidative stress has been highlighted in the pathogenesis of neuropsychiatric disorders. A body of clinical and preclinical evidence indicates that psychiatric diseases are characterized by higher levels of oxidative biomarkers and with lower levels of antioxidant defense biomarkers in the brain and peripheral tissues. In this article, we review current knowledge on the role of the oxidative stress in psychiatric diseases, based on clinical trials and animal studies, in addition, we analyze the effects of drug-induced modulation of oxidative balance and explore pharmacotherapeutic strategies for oxidative stress reduction.

show abstract

Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: Long-term effects of perinatal phencyclidine administration

Cited by 71 publications

References 57 publications

Taurine and glutathione in plasma and cerebrospinal fluid in olanzapine treated patients with schizophrenia

Taurine and glutathione in plasma and cerebrospinal fluid in olanzapine treated patients with schizophrenia

Oxidative Stress and Schizophrenia

Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism

Contact Info

Product

Resources

About